Tbo-filgrastim Side Effects
Medically reviewed by Drugs.com. Last updated on Jun 12, 2022.
Applies to tbo-filgrastim: subcutaneous solution.
Serious side effects of Tbo-filgrastim
Along with its needed effects, tbo-filgrastim may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking tbo-filgrastim:
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- bone pain
- fever
- pinpoint red spots on the skin
- unusual bleeding or bruising
Rare
Incidence not known
- Blisters or fever sores on the skin
- bloody or cloudy urine
- chest pain or tightness
- difficulty with swallowing
- dizziness
- fast heartbeat
- hives, itching, or skin rash
- pain in the upper left part of the stomach or at the tip of the left shoulder
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- trouble breathing
- unusual weakness
- weight gain
Other side effects of Tbo-filgrastim
Some side effects of tbo-filgrastim may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Diarrhea
- pain in the arms or legs
Incidence not known
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- lack or loss of strength
For Healthcare Professionals
Applies to tbo-filgrastim: subcutaneous solution.
Cardiovascular
Very common (10% or more): Thrombocytopenia (up to 34%)
Frequency not reported: Aortitis, capillary leak syndrome
In a clinical trial, thrombocytopenia occurred in 34% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.
Gastrointestinal
In a clinical trial, diarrhea occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.[Ref]
Common (1% to 10%): Diarrhea
Frequency not reported: Vomiting[Ref]
Musculoskeletal
Common (1% to 10%): Bone pain, extremity pain
Frequency not reported: Myalgia[Ref]
In a clinical trial, extremity pain occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.[Ref]
Other
In a clinical trial, pyrexia occurred in 8% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.[Ref]
Common (1% to 10%): Pyrexia
Postmarketing reports: Asthenia, fatigue[Ref]
Nervous system
Common (1% to 10%): Headache
In a clinical trial, headache occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.
Immunologic
Common (1% to 10%): Anti-drug antibodies to this drug
Hematologic
Frequency not reported: Fatal splenic rupture, leukocytosis, sickle cell disorders[Ref]
Dermatologic
Frequency not reported: Cutaneous vasculitis
Postmarketing reports: Acute febrile neutrophilic dermatosis, Sweet's syndrome[Ref]
Oncologic
Frequency not reported: Potential for tumor growth stimulatory effects on malignant cells
Hypersensitivity
Frequency not reported: Serious allergic reactions
Respiratory
Frequency not reported: Acute respiratory distress syndrome
Renal
Frequency not reported: Glomerulonephritis
More about tbo-filgrastim
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: colony stimulating factors
- En español
Patient resources
Other brands
Related treatment guides
References
1. Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA. 2013.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.